Provided by Tiger Trade Technology Pte. Ltd.

Verrica Pharmaceuticals Inc.

5.47
-0.0200-0.36%
Post-market: 5.470.00000.00%16:10 EDT
Volume:38.66K
Turnover:207.07K
Market Cap:93.97M
PE:-3.26
High:5.49
Open:5.36
Low:5.21
Close:5.49
52wk High:9.82
52wk Low:3.28
Shares:17.18M
Float Shares:6.78M
Volume Ratio:0.45
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6800
EPS(LYR):-14.7812
ROE:-240.35%
ROA:-14.74%
PB:3.80
PE(LYR):-0.37

Loading ...

Verrica Pharmaceuticals Inc - Torii to Fund First $40 Mln of Phase 3 Trial Costs

THOMSON REUTERS
·
Jan 07

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating Ycanth® (Vp-102) for the Treatment of Common Warts

THOMSON REUTERS
·
Jan 07

Verrica Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Charles Frantzreb

Reuters
·
Dec 30, 2025

Verrica Pharmaceuticals Grants New Equity Awards to Executives Under 2018 Plan

Reuters
·
Dec 30, 2025

Top Premarket Decliners

MT Newswires Live
·
Dec 16, 2025

Verrica Pharmaceuticals CMO Noah L. Rosenberg Acquires Common Shares

Reuters
·
Nov 26, 2025

Director and 10% Owner Paul B. Manning Reports Acquisition of Verrica Pharmaceuticals Inc. Common Shares

Reuters
·
Nov 26, 2025

Verrica Pharmaceuticals CEO Jayson Rieger Reports Acquisition of Common Shares

Reuters
·
Nov 26, 2025

Interim CFO John J. Kirby Acquires Common Shares of Verrica Pharmaceuticals Inc

Reuters
·
Nov 26, 2025

BRIEF-Verrica Pharmaceuticals Enters Securities Purchase Agreement With Institutional Investors

Reuters
·
Nov 25, 2025

Verrica Pharmaceuticals Inc - Enters Securities Purchase Agreement With Institutional Investors - SEC Filing

THOMSON REUTERS
·
Nov 25, 2025

Verrica Pharmaceuticals Inc - to Sell 6.5 Mln Shares in Private Placement - SEC Filing

THOMSON REUTERS
·
Nov 25, 2025

Verrica Pharmaceuticals Raises $50 Million in Private Placement Financing

Reuters
·
Nov 24, 2025

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

THOMSON REUTERS
·
Nov 24, 2025

Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma

Reuters
·
Nov 18, 2025

Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025

Reuters
·
Nov 15, 2025

Verrica Pharmaceuticals Inc - Qtrly Net Loss per Share, Basic and Diluted $0.03

THOMSON REUTERS
·
Nov 15, 2025

Verrica Pharmaceuticals Q3 Income From Operations USD 1.627 Million

THOMSON REUTERS
·
Nov 15, 2025

Verrica Pharmaceuticals Reports Positive Phase 2 Results for VP-315 in Basal Cell Carcinoma

Reuters
·
Nov 10, 2025

Verrica Pharmaceuticals Presents New Data on Vp-315 From Its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40TH Society for Immunotherapy of Cancer Annual Meeting

THOMSON REUTERS
·
Nov 10, 2025